IL321700A - Salts and solid forms of sonrotoclax intermediate - Google Patents

Salts and solid forms of sonrotoclax intermediate

Info

Publication number
IL321700A
IL321700A IL321700A IL32170025A IL321700A IL 321700 A IL321700 A IL 321700A IL 321700 A IL321700 A IL 321700A IL 32170025 A IL32170025 A IL 32170025A IL 321700 A IL321700 A IL 321700A
Authority
IL
Israel
Prior art keywords
sonrotoclax
salts
solid forms
solid
forms
Prior art date
Application number
IL321700A
Other languages
Hebrew (he)
Original Assignee
Beone Medicines I Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beone Medicines I Gmbh filed Critical Beone Medicines I Gmbh
Publication of IL321700A publication Critical patent/IL321700A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL321700A 2022-12-27 2023-12-26 Salts and solid forms of sonrotoclax intermediate IL321700A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022142316 2022-12-27
PCT/CN2023/141989 WO2024140692A1 (en) 2022-12-27 2023-12-26 Salts and solid forms of sonrotoclax intermediate

Publications (1)

Publication Number Publication Date
IL321700A true IL321700A (en) 2025-08-01

Family

ID=91716479

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321700A IL321700A (en) 2022-12-27 2023-12-26 Salts and solid forms of sonrotoclax intermediate

Country Status (10)

Country Link
US (1) US20250320209A1 (en)
EP (1) EP4642776A1 (en)
JP (1) JP2026503230A (en)
KR (1) KR20250127312A (en)
CN (1) CN119301117A (en)
AU (1) AU2023416871A1 (en)
IL (1) IL321700A (en)
MX (1) MX2025007584A (en)
TW (1) TW202434586A (en)
WO (1) WO2024140692A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437772B (en) * 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2 inhibitors
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
MX2023014275A (en) * 2021-06-02 2024-03-06 Beigene Switzerland Gmbh Methods of treating b-cell malignancy using bcl-2 inhibitor.
TW202400163A (en) * 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 Methods of treating myeloid malignancies using bcl-2 inhibitor

Also Published As

Publication number Publication date
TW202434586A (en) 2024-09-01
KR20250127312A (en) 2025-08-26
WO2024140692A1 (en) 2024-07-04
CN119301117A (en) 2025-01-10
US20250320209A1 (en) 2025-10-16
JP2026503230A (en) 2026-01-28
AU2023416871A1 (en) 2025-08-14
MX2025007584A (en) 2025-09-02
EP4642776A1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
SI4185580T1 (en) Solid state forms of belumosudil and belumosudil salts
IL288062A (en) Solid state forms of tafamidis and salts thereof
IL321357A (en) Inhibitors of kif18a and uses thereof
GB202103594D0 (en) Antagonist of PCSK9
IL314320A (en) Compounds and methods of use
IL304312A (en) Pharmaceutically acceptable salts of psilocin and uses thereof
IL318393A (en) Aza-quinazoline compounds and methods of use
IL316654A (en) Preparation and uses of 7-azaindenoisoquinolines
GB202411655D0 (en) Application of circHIF1a
GB202401487D0 (en) Salts and polymorphs of mitragynine and 3-deuteromitragynine
IL314277A (en) Anti-b7-h3 compounds and methods of use
IL314594A (en) Heterocyclic compounds and methods of use
IL326152A (en) Solid state forms of gusacitinib
PL4441028T3 (en) Salt of s-oxprenolol
HK40128909A (en) Salts and solid forms of sonrotoclax intermediate
CA3277370A1 (en) Salts and solid forms of sonrotoclax intermediate
LT4027976T (en) Rifabutin compositions and method of making
IL312041A (en) R-ketamine salts and methods of use thereof
GB202316444D0 (en) Salts of opicapone
IL319769A (en) Solid state forms of mesdopetam and salts therofsolid state forms of mesdopetam and salts therof
CA3279207A1 (en) Solid state forms of brilaroxazine and brilaroxazine salts
IL326153A (en) Solid state forms of gusacitinib
IL319179A (en) Solid state forms of denifanstat
GB202215264D0 (en) Use of urolithins
GB202315697D0 (en) Compounds and methods of use